Previous 10 | Next 10 |
Data show how AbCellera is expanding the reach of T-cell engagers with: CD3-binding antibodies that consistently generate T-cell engagers with potent tumor-cell killing and low cytokine release across multiple tumor targets, including PSMA, B7-H4, and 5T4 Costimulatory CD28-bind...
AbCellera (Nasdaq: ABCL) will announce its first quarter 2024 financial results on Tuesday, May 7, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that ...
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Bloom Burton Healthcare Conference on Tuesday, April 16, 2024, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time). A live audio webcast of the presentation may be accessed through a link that will...
2024-03-11 12:23:20 ET More on AbCellera, Biogen Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) AbCellera: Victim Of Its Own Success AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript Biogen Alzheimer’s drug...
AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. “Delivering biologics across the blood brain ba...
2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...
AbCellera (Nasdaq: ABCL) today announced that its scientists will present four posters with data from its T-cell engager programs and platform at the American Association for Cancer Research (AACR) Annual Meeting 2024, to be held April 5 to 10 at the San Diego Convention Center. With its T-...
2024-02-26 06:55:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors know that the world of biotech stocks is home to a great percentage of opportunities that can triple and quadruple their capital. It’s also fairly easy to identify such sto...
2024-02-23 17:38:31 ET More on AbCellera Biologics AbCellera Biologics Inc. (ABCL) Q4 2023 Earnings Call Transcript AbCellera Biologics: Continuing To Expand Partnerships AbCellera: Difficult 2023 Suggests Business Model Should Pivot In 2024 AbCellera Biologi...
AbCellera (Nasdaq: ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company’s Board of Directors for personal reasons, effective March 7, 2024. “AbCellera continues to expand the frontier of biotech, a nefariously difficult an...
News, Short Squeeze, Breakout and More Instantly...
AbCellera Biologics Inc. Company Name:
ABCL Stock Symbol:
NASDAQ Market:
2024-05-08 17:30:13 ET KeyBanc analyst issues OVERWEIGHT recommendation for ABCL on May 8, 2024 02:46AM ET. The previous analyst recommendation was Overweight. ABCL was trading at $3.84 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curr...
2024-05-08 04:30:12 ET Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL) Q1 2024 Earnings Call May 07, 2024 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics (ABCL) Q1 2024 Earnings Call Tran...
AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. “We continue to execute on advancing our internal pipeline, completing capital investment...